TrialLupus science & medicine2020

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.

Thomas Dörner et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.